Be the first person to write a business review for Allermed Laboratories, Inc.

Alnylam Pharmaceuticals, Inc. company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Its lead RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, it reported positive results from its Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In April 2008, it initiated a second Phase II human clinical trial, which is, as of December 31, 2008, ongoing, to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients naturally infected with RSV. As of December 31, 2008, it formed collaborations with Cubist Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd., for the development and commercialization of products for RSV.

Founded in 1992, Alpha Innotech Corporation develops, manufactures and markets digital imaging and detection systems for the Life Science research and Drug Discovery markets. Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets. Our customers include pharmaceutical and biotechnology companies as well as universities, medical centers, government research institutes and agencies worldwide. On October 28, 2009 Alpha Innotech became part of Cell Biosciences.

AlphaVax, Inc. company was founded in 1998 by Robert Johnston, Nancy Davis, and Jonathan Smith, AlphaVax's chief scientific officer. AlphaVax, Inc. company is developing new vaccines for cancers and infectious diseases such as HIV/AIDS, Ebola, influenza, and other viral maladies. AlphaVax relies on a proprietary alphavaccine system that genetically alters diseased cells and transforms them into a vaccine when they attempt to replicate. Its technology could be used to develop preventative vaccines and therapeutic vaccines. Its pipeline consists of early-stage candidates. AlphaVax receives funding through partnerships and grants.

Alseres Pharmaceuticals, Inc. was founded in 1972 and is headquartered in Hopkinton, Massachusetts. The biotechnology company is developing therapies and diagnostics related to nervous system conditions, such as spinal cord injury, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). Its lead candidate is Altropane, a molecular imaging agent for diagnosing Parkinson's disease and ADHD. Another candidate, Cethrin, aims to repair nerve damage caused by spinal cord injury; Alseres licensed Cethrin from Canadian firm BioAxone Therapeutic in 2006.

Althea Technologies provides services that help drug developers speed up the drug discovery and testing process, as well as reduce risks and costs associated with research and development efforts. Founded in 1998 by co-chairs Francois Ferre and Magda Marquet -- who hold Ph.D.s in molecular oncology and biochemical engineering -- the company assists in the development process from discovery through testing, regulatory support, and contract manufacturing stages. Services include gene expression analysis, protein production, and therapeutic and vaccine product manufacturing for clinical trials.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.